Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

BACKGROUND: Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by binding to an ubiquitin ligase. In this work, we explored the antitumoral activity o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Exp Clin Cancer Res
Hlavní autoři: Noblejas-López, María del Mar, Nieto-Jimenez, Cristina, Burgos, Miguel, Gómez-Juárez, Mónica, Montero, Juan Carlos, Esparís-Ogando, Azucena, Pandiella, Atanasio, Galán-Moya, Eva M., Ocaña, Alberto
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717344/
https://ncbi.nlm.nih.gov/pubmed/31470872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1387-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky